MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

In some good news for the US vaccines developer, whose stock has fallen 66% in the past 12 months, Moderna on Friday ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

Georgia officials halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 ...

Flagship Pioneering partners with CUHP and MTI to advance research, clinical translation, and talent development in the UK. The collaboration gives Flagship’s companies access to Cambridge’s resources ...

This diverse pipeline exemplifies Moderna's road map to extend its mRNA technology into new categories, positioning itself as a more diversified and mature commercial-stage biotech company.

Only by tapping into this earlier work was Moderna able to bring its mRNA vaccines to market so ... teams can leverage the At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum ...

With only one commercial product – the COVID-19 vaccine – Moderna faces pressure to diversify its pipeline rapidly. As the company invests heavily in expanding its non-COVID mRNA vaccine ...

H5N1 vaccines have been previously licensed, and millions are in the national stockpile. But even with the news of the ...